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Abstract
Introduction: It is generally believed that incretin-based therapies are effective in patients possessing certain levels
of preserved b-cell function. So far, there are no reports that show the effectiveness of dipeptidyl peptidase-4
inhibitors in patients who absolutely lack the capacity for endogenous insulin secretion.
Case presentation: This report describes the efficacy of sitagliptin in three Japanese patients (a 91-year-old
Japanese woman with type 1 diabetes, a 54-year-old Japanese man with type 2 diabetes and a 30-year-old
Japanese man with features of both type 1 and type 2 diabetes) who had no detectable post-meal C-peptide
levels. Although they were receiving intensive insulin therapy together with some oral hypoglycemic agents, their
glycemic control remained poor. Sitagliptin was added to the ongoing therapeutic regimen to provide better
glycemic control. Although these patients had mild hypoglycemia, effective reductions of hemoglobin A1c levels
were observed without any adverse events in the liver and kidney during the following 24 weeks. Two of the
patients were able to reduce their insulin doses, and one of the patients could discontinue one of the oral
hypoglycemic agents. There was no weight gain or gastrointestinal complaints among the three patients. Post-
meal C-peptide levels remained undetectable after sitagliptin treatment.
Conclusion: This report demonstrates that sitagliptin is effective and safe as an add-on therapy to insulin in
reducing blood glucose levels in patients who absolutely lack the capacity for endogenous insulin secretion. The
improvement seen in glycemic control could not be due to enhanced endogenous insulin secretion, since post-
meal C-peptide levels remained undetectable after sitagliptin treatment, but it could be a result of other factors
(for example, suppression of glucagon levels). However, the glucagon-suppressive effect of sitagliptin is known to
be rather weak and short-lived. Given this background, a novel hypothesis that the glycemic effects of this drug
may be caused by mechanisms that are independent of the glucagon-like peptide 1 axis (extra-pancreatic effect)
will be discussed.
Introduction
The incretin-based drugs glucagon-like peptide 1 (GLP-1)
receptor agonists and dipeptidal peptidase 4 (DPP-4) inhi-
bitors are a new class of drugs for the treatment of type 2
diabetes [1]. GLP-1 is released from intestinal L cells in
response to the ingestion of a meal and plays an important
role in glucose homeostasis by stimulating glucose-depen-
dent insulin secretion and inhibiting glucagon secretion
[1-3]. Currently, two GLP-1 analogues (exenatide and lira-
glutide) and four DPP-4 inhibitors (sitagliptin, vildagliptin,
saxagliptin and alogliptin) are on the market, and many
others are under development. The latter class of drugs
works by inhibiting the DPP-4 enzyme that degrades GLP-
1, thereby stabilizing the intact (active) form of GLP-1.
Active GLP-1 stimulates glucose-dependent insulin bio-
synthesis and release, and GLP-1 also suppresses glucagon
release, delays gastric emptying and increases satiety. In
contrast to GLP-1 analogues, DPP-4 inhibitors have no
effects on gastric emptying and body weight [1-3]. Sitaglip-
tin is the first DPP-4 inhibitor on the market. It is used
as monotherapy or in combination with metformin,
thiazolidinedione or sulfonylurea. It is also available in a
combination product with metformin. Furthermore, its
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the USA based on the large amount of clinical data [4].
Incretin-based therapies are associated with enhanced
b-cell function, making them a good treatment option
early in the disease when the patients still maintain suffi-
cient levels of b-cell function [1-3]. However, it is unclear
whether incretin-based drugs are still effective in patients
without the capacity for endogenous insulin secretion
(that is, no residual b-cell functions; for example, advanced
type 2 diabetes or type 1 diabetes). Animal models have
demonstrated that DPP-4 inhibitors improve glucose
intolerance in early-stage diabetes, but not in the late stage
of the disease [5], suggesting that DPP-4 inhibitors are
more effective in the presence of functional b-cells. How-
ever, whether this is the case in humans has not been
investigated. The possibility of using GLP-1 analogues in
patients with type 1 diabetes is now emerging [6]. As in
the animal model [5], it has been proposed that the ideal
candidates for this treatment strategy are individuals with
type 1 diabetes who still have significant preserved b-cell
a c t i v i t y[ 6 ] .S of a r ,n os t u d yh a sd e m o n s t r a t e dw h e t h e r
DPP-4 inhibitors are also effective with those patients who
absolutely lack the capacity for endogenous insulin secre-
tion. The present report presents three cases (one with
type 1 diabetes, one with type 2 diabetes and one with fea-
tures of both type 1 and type 2 diabetes) where the addi-
tion of sitagliptin to the ongoing insulin therapy was
considerably effective in the patients whose insulin secre-
tory capacity (residual b-cell function) was severely
diminished.
Case presentation
Case 1 is a 91-year-old Japanese woman who had been
diagnosed with acute onset of type 1 diabetes two years
earlier and had been using various doses and types of
insulin since that diagnosis. Her endogenous insulin
secretory capacity was almost completely lost since her
post-meal (approximately two hours after a meal) C-
peptide levels were undetectable (below 0.1 ng/ml) and
24-hour urine C-peptide levels were below 1.1 mg/day
(normal range, 20.1 to 155 mg/day). Her insulin antibo-
dies were positive at diagnosis. Why this patient devel-
oped acute onset of autoimmune type 1 diabetes with
absolute insulin deficiency is elusive.
This may be an atypical case. Her post-meal glucagon
level was 130 pg/ml (normal range, 23 to 197 pg/ml).
Her body mass index (BMI) was 21.5 (body weight/body
height = 40.4 kg/137 cm). Her hemoglobin A1c
(HbA1c) level was above 9.5% in the three months prior
to this study. Sitagliptin (25 mg/day) was added to the
ongoing therapeutic regimen to provide better control
of her diabetes. At that time, she was using premixed
biphasic insulin aspart (30% insulin aspart and 70%
protamine-complexed insulin aspart; Novorapid 30 Mix
(Novo Nordisk A/S, Bagsvaerd, Denmark) three times
daily before each meal (14U, 4U and 14U, respectively).
She was also taking 50 mg of miglitol three times daily
and 150 mg/day aliskiren. Her post-meal blood glucose
was 252 mg/dl, and her HbA1c level was 9.6% at the
start of sitagliptin therapy (at baseline). She had occa-
sionally mild hypoglycemia after starting sitagliptin,
which she could manage by taking glucose drinks by
herself. Her HbA1c levels were followed for 24 weeks
and were reduced from 9.6% to 7.4% (2.2% reduction)
(Figure 1). The doses of insulin remained unchanged,
but at 20 weeks, because of the relatively good glycemic
control for her age, miglitol was discontinued. Because
her blood pressure started to rise at around 20 weeks,
150 mg/day aliskiren was replaced with 4 mg/day cande-
sartan. Her post-meal C-peptide levels repeatedly
remained undetectable (below 0.1 ng/ml) after sitagliptin
treatment. No adverse events were observed in the kid-
ney (assessed on the basis of blood urea nitrogen and
creatinine levels) or liver (assessed by glutamate oxaloa-
cetate transaminase, glutamate pyruvate transaminase,
alkaline phosphatase and g-glutamyl traspeptidase func-
tion). No weight gain or gastrointestinal complaints
were noted.
Before and during the sitagliptin treatment, no special
difference in diet management or physical exercise was
noted.
Case 2 is a 30-year-old Japanese man who was trans-
ferred to the emergency department with diabetic ketoa-
cidosis and was initially diagnosed with type 1 diabetes
three years prior to this study. He has been using differ-
ent doses and types of insulin since that diagnosis. How-
ever, his glutamic acid decarboxylase (GAD) and insulin
antibodies were negative (below detectable range). There-
fore, this patient has features of both type 1 and type 2
diabetes. However, because of his clinical picture, this
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Figure 1 Changes of hemoglobin A1c (HbA1c) levels after
adding sitagliptin to the ongoing therapeutic regimen.
Sitagliptin was added at week 0. The changes of HbA1c levels of
each patient were followed from 4 weeks prior to treatment (-4W)
until 24 weeks after treatment.
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betes, which is rare in Caucasian populations but com-
prises approximately 10% of type 1 diabetes cases in
Japan [7]. His endogenous insulin secretory capacity was
almost completely lost, since his post-meal C-peptide
levels were repeatedly undetectable (below 0.1 ng/ml).
His post-meal glucagon level was 107 pg/ml (normal
range, 23 to 197 pg/ml). His BMI was 17.5 (body weight/
body height = 52 kg/172 cm). His HbA1c level was above
8% in the three months prior to this study. Sitagliptin
(50 mg/day) was added to the therapeutic regimen to try
to achieve better control of his diabetes. At that time, he
was using premixed biphasic insulin aspart (30% insulin
aspart and 70% protamine-complexed insulin aspart;
Novorapid 30 MIX) three times daily before each meal
(15U, 7U and 16U, respectively). He was also taking
625 mg metformin three times daily and 75 mg miglitol
three times daily. His post-meal blood glucose level was
242 mg/dl, and his HbA1c level was 8.1% at baseline. In
the first month after starting sitagliptin, he had occa-
sional mild hypoglycemia, which he could manage by tak-
ing glucose drinks by himself. He had no hypoglycemic
events after the second month of sitagliptin therapy. His
HbA1c level was followed for 24 weeks and was reduced
from 8.1% to 7.1% (1.0% reduction, Figure 1). His post-
meal C-peptide levels repeatedly remained undetectable
(below 0.1 ng/ml) after the start of sitagliptin treatment.
No adverse events were observed in kidney or liver func-
tion. No weight gain or gastrointestinal complaints were
noted. At eight weeks, he could reduce the insulin dose
by 2U before each meal. The doses of other drugs
remained unchanged. Before and during sitagliptin treat-
ment, no special difference in diet management or physi-
cal exercise was noted.
Case 3 is a 54-year-old Japanese man who had been
diagnosed with type 2 diabetes 22 years earlier and had
been using different types and doses of insulin since
that diagnosis. His endogenous insulin secretory capacity
was almost completely lost, since his post-meal C-
peptide levels were repeatedly undetectable (below
0.1 ng/ml). His GAD and insulin antibodies were nega-
tive. His BMI was 22.9 (body weight/body height =
64 kg/167 cm). His HbA1c level was above 7.5% in the
three months prior to this study. Sitagliptin (50 mg/day)
was added to the patient’s therapeutic regimen to try to
achieve better control of his diabetes. At that time, he
was using insulin lispro (Humalog, Eli Lilly and Com-
pany, Indianapolis, Indiana, USA) three times daily
before each meal (8U, 10U and 10U, respectively) and
insulin glargine (Lantas, Sanofi-Aventis, Paris, France)
before going to bed (20U) and was also taking 2.5 mg/
day rosuvastatin, 250 mg metformin three times daily,
5 mg/day amlodipine and 2 mg/day doxazosin mesylate.
His post-meal blood glucose level was 221 mg/dl, and
his HbA1c level was 7.5% at baseline. He had occasion-
ally mild hypoglycemia after starting sitagliptin, which
he could manage by taking glucose drinks by himself.
His HbA1c level was followed for 24 weeks and was
reduced from 7.5% to 6.5% (1.0% reduction) (Figure 1)
at six weeks. Thus, at that time, the dose of insulin was
reduced by 2U before each meal and at bedtime. The
doses of other drugs remained unchanged. At 24 weeks,
the patient’s HbA1c level was 6.9%, which was still
within an acceptable range. His post-meal C-peptide
levels repeatedly remained undetectable (below 0.1 ng/
ml) after sitagliptin treatment. No adverse events were
observed in kidney or liver function. No weight gain or
gastrointestinal complaints were noted. Before and dur-
ing the sitagliptin treatment, no special difference in
diet management or physical exercise was noted.
Discussion
Physicians often encounter patients whose blood glucose
control is rather difficult, even with intensive insulin
therapy combined with maximally tolerated doses of
oral hypoglycemic agents (OHAs). One of the features
of such patients is that they lack the capacity for endo-
genous insulin secretion. Increasing the dosage of insu-
lin units may be a solution to this problem; however, in
practice, this can cause an increased risk of hypoglyce-
mia and weight gain. Incretin-based drugs (GLP-1
receptor agonists and DPP-4 inhibitors) may help such
patients attain desirable glycemic control. Furthermore,
these drugs induce benefits in terms of post-prandial
hyperglycemia control in addition to positive effects on
b-cell function and possible b-cell preservation [1-3].
Recently, sitagliptin, the first DPP-4 inhibitor launched
on the market, has been approved for use in combination
with insulin. Sitagliptin combined with insulin significantly
reduces blood glucose levels over the four-hour period fol-
lowing the meal test. Serum C-peptide and insulin levels
were found to significantly increase over the four-hour
period following the meal with sitagliptin in comparison
to that in patients receiving a placebo [4]. However, few
studies have demonstrated whether incretin-based drugs
are still effective in patients whose insulin secretory capa-
cities (residual b-cell function) are not preserved. Very
recently, GLP-1 and its analogue were shown to be effec-
tive in C-peptide-negative patients with type 1 diabetes,
though this is an off-label use of this drug [8,9]. In these
reports, C-peptide remained undetectable after treatment
with these agents, suggesting no improvement in b-cell
function was observed. This is somewhat in contrast to
the commonly accepted idea that GLP-1 augments b-cell
function [1]. So far, there are no publications that have
reported the effectiveness of DPP-4 inhibitors in patients
who absolutely lack the capacity for endogenous insulin
secretion. This report describes the results of three such
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ongoing intensive insulin therapy, and the glycemic con-
trol was shown to be effectively improved. Two of the
patients were able to reduce their insulin doses (case 2
and case 3), and one patient was able to discontinue one
of the OHAs (case 1). Interestingly, post-meal C-peptide
levels remained undetectable in all three of the patients
after sitagliptin treatment, suggesting that no improve-
ment of b-cell function was observed in association with
this drug. Although the limit of detection of C-peptide in
the assay used in this report was 0.1 ng/ml (measured at
Mitsubishi Kagaku, Tokyo, Japan), one cannot fully
exclude the possibility that minimal changes in C-peptide
levels in these patients may have escaped the analysis.
So, what are the potential mechanisms that can cause
the reduced glucose levels with sitagliptin? A number of
explanations can be postulated.
First, the glycemic effect observed in these patients
may be due to suppression of glucagon levels. The
mechanism by which GLP-1 suppresses glucagon secre-
tion is far from being elucidated, and furthermore it is
unclear whether endogenous insulin is a required factor
for this effect. On the basis of the data from the present
case report and others [8,9], one might be able to envi-
sage that the effect of GLP-1 on glucagon secretion
would not be dependent on endogenous insulin, since
insulin secretion remained absent after the treatment of
incretin-based drugs. Further, it was reported that the
glucagon-suppressive effects of sitagliptin (or other
DPP-4 inhibitors) are very small and short-lived, and
also its effects on insulin secretion are somewhat not
evident [10]. Therefore, it is unlikely that reduction of
glucagon levels by sitagliptin can fully explain the
reduced glucose levels. As a matter of fact, the post-
prandial glucagon levels before the addition of sitagliptin
were within the normal range in the patients described
in this report (cases 1 and 2). It was not possible to
measure the glucagon levels after sitagliptin treatment,
since glucagon has not been commercially measurable
in Japan since mid-2010.
Second, the improvement seen in glycemic control
with sitagliptin therapy could be due to the pharmacolo-
gical effects of GLP-1, such as delayed gastric emptying
and body weight loss. However, this does not seem to
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Figure 2 Schematic presentation of glucagon-like peptide-1 (GLP-1)-dependent and GLP-1-independent actions of sitagliptin.
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4 inhibitors, including sitagliptin, do not have any clear
effects on these parameters [1-3]. The patients described
in this case report did not have any changes in body
weight or gastrointestinal complaints.
Finally, the background information described above
might suggest that the glucose-lowering effect of sitaglip-
tin not only occurs via the GLP-1 axis but is also mediated
by novel mechanisms including extra-pancreatic signal
transduction pathways. Specifically, sitagliptin may have
an independent role in the regulation of hepatic glucose
output, glycogenesis, gluconeogenesis, glycolysis or periph-
eral (skeletal muscle or adipose tissues) glucose uptake
different from that of insulin or glucagon action. Alterna-
tively, it may have a novel glycemic effect, such as inhibit-
ing glucose absorption by the intestine. These putative
effects are illustrated in Figure 2. It remains to be investi-
gated whether similar or different results will be obtained
with other DPP-4 inhibitors. To further explore these
issues, it is of significance to perform gene chip (microar-
ray) analysis and identify genes regulated by sitagliptin
(or other DPP-4 inhibitors), followed by cellular
investigations.
T h es t r e n g t ho ft h i sw o r ki st h a ts i m i l a rr e s u l t sw e r e
obtained from patients who have very different diabetic
backgrounds. But the common denominator is that
these patients are absolutely insulin-deficient. A limita-
tion of this work is that this report is based on just
three observational case studies. Well-designed and ade-
quately powered randomized clinical trials are necessary
to draw well-validated conclusions.
Conclusions
The cases presented in this report demonstrate that sita-
gliptin is still effective and safe in reducing blood glu-
cose levels in those patients who have no residual b-cell
function. However, one should keep in mind that sita-
gliptin should be used not as a replacement therapy but
as an add-on to insulin with such absolutely insulin-
deficient patients.
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patients for publication of this case report and any
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